Immunic is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases.

CoSec was recommended to us by several German biotech companies. We have been very pleased with how easy they have made it to estabish and administer our Australian subsidiary.

The whole process has run smoothly. Our Phase 1 trials commenced successfully late in 2019, and we look forward to working with CoSec into the future.

Erika von der Decken
Immunic AG

The Problem

Immunic was interested in conducting clinical trials in Australia, but they needed support to manage this expansion and to administer an Australian subsidiary in line with local tax regulations and law. They also needed guidance to find key local partners to get their clinical trial up and running.

The Solution

With several recommendations from other German biotech companies, Immunic chose to partner with CoSec. Our team of tax, finance and compliance specialists made the whole process easy, with seamless support through the initial company incorporation process, to identifying key partners, to the ongoing management of Immunic’s Australian subsidiary.


Immunic commenced Phase 1 of its clinical trials in Australia in September 2019.

Ready to Expand Your Business?

Talk to the experts who can support and guide you in your Australian and US growth journey.